ライフサイエンスコーパス: ACHD

1 ACHD experts can provide expertise in the management of

2 ACHD patients continue to be afflicted by increased mort

3 CHD and 38,557 non-ACHD patients listed, 237 ACHD and 6,377 non-ACHD patients died or were delisted d

4 patients initially listed as status 1A (24% ACHD vs. 17% non-ACHD after 180 days; p < 0.001).

5 Among 1,290 ACHD and 38,557 non-ACHD patients listed, 237 ACHD and 6

6 vide a quality of care assessment tool for 6 ACHD conditions.

7 METHODS AND Of 25 790 ACHD patients in an international multicenter registry,

8 support a model of specialized care for all ACHD patients.

9 ary care physicians,adult cardiologists, and ACHD specialists to provide optimal care for these women

10 ferral rates to specialized ACHD centers and ACHD patient mortality rates between 1990 and 2005 in th

11 ically significant reductions in overall and ACHD mortality in the men, but not in the women.

12 These findings might assist ACHD programs in developing strategies to identify and r

13 here were no significant differences between ACHD and non-ACHD patients listed as status 1B or 2.

14 ant difference in peak VO2 was found between ACHD and heart failure patients of corresponding NYHA cl

15 es were observed among patients with complex ACHD, Fontan physiology, and Eisenmenger syndrome.

16 ise testing was performed in 335 consecutive ACHD patients (age, 33+/-13 years), 40 non-congenital he

17 f noncardiac causes of death in contemporary ACHD patients.

18 barriers to adult congenital heart disease (ACHD) care, as perceived by pediatric cardiologists (PCs

19 Data from Adult Congenital Heart Disease (ACHD) centres that follow up Tetralogy of Fallot patient

20 The adult with congenital heart disease (ACHD) faces medical, surgical, and psychosocial issues t

21 ns for adults with congenital heart disease (ACHD) in the U.S.

22 atients with adult congenital heart disease (ACHD) is rapidly increasing.

23 uces atherosclerotic coronary heart disease (ACHD) mortality, ACHD mortality combined with a new conf

24 Adult congenital heart disease (ACHD) patients have ongoing morbidity and reduced long-t

25 mortality in adult congenital heart disease (ACHD) patients.

26 zed care for adult congenital heart disease (ACHD) patients.

27 anagement of adult congenital heart disease (ACHD) patients.

28 atients with adult congenital heart disease (ACHD) report limitations in exercise capacity, we hypoth

29 research in adult congenital heart disease (ACHD) was convened in September 2004 under the sponsorsh

30 r many adults with congenital heart disease (ACHD).

31 among adults with congenital heart disease (ACHD).

32 arallel, a significant reduction in expected ACHD patient mortality was observed after year 2000 (rat

33 The number of hospital admissions for ACHD in the U.S. more than doubled between 1998 and 2005

34 of guidelines endorsing specialized care for ACHD patients.

35 ical status is disproportionately common for ACHD patients listed as status 1A.

36 mote quality measurement and improvement for ACHD patients.

37 g for clinical worsening was more likely for ACHD patients initially listed as status 1A (24% ACHD vs

38 transplant listing, impact the outcomes for ACHD patients listed for heart transplantation.

39 d in development of the first set of QIs for ACHD care based on published data, guidelines, and a mod

40 Poor exercise capacity identifies ACHD patients at risk for hospitalization or death.

41 e 2014 Consensus Statement on Arrhythmias in ACHD patients and the 2015 European Society of Cardiolog

42 may have demonstrated a possible benefit in ACHD prognosis from effective lipid intervention in wome

43 Exercise capacity is depressed in ACHD patients (even in allegedly asymptomatic patients)

44 tion factor 15 with cardiovascular events in ACHD.

45 fied recommendations for ICD implantation in ACHD patients for the first time.

46 asoning when deciding on ICD implantation in ACHD patients, therefore, remains vital.

47 nce of anemia and its relation to outcome in ACHD remain unknown.

48 oxygen consumption (peak VO2) was reduced in ACHD patients compared with healthy subjects of similar

49 lity of these ICD recommendations for SCD in ACHD patients.

50 NHLBI on the current state of the science in ACHD and barriers to optimal clinical care, and to make

51 using input from physicians specializing in ACHD to assess the symptoms patients associate with dise

52 t disease be guided by clinicians trained in ACHD.

53 Anemia is not uncommon in ACHD patients attending tertiary services and is associa

54 g due to clinical worsening within 1 year in ACHD included: estimated glomerular filtration rate <60

55 the QIs to a 9-member panel of international ACHD experts.

56 tic coronary heart disease (ACHD) mortality, ACHD mortality combined with a new confirmed nonfatal my

57 ly listed as status 1A (24% ACHD vs. 17% non-ACHD after 180 days; p < 0.001).

58 ACHD patients listed, 237 ACHD and 6,377 non-ACHD patients died or were delisted due to clinical wors

59 Among 1,290 ACHD and 38,557 non-ACHD patients listed, 237 ACHD and 6,377 non-ACHD patien

60 significant differences between ACHD and non-ACHD patients listed as status 1B or 2.

61 known how current criteria, derived from non-ACHD populations, used to determine priority at the time

62 tigate outcomes of ACHD in comparison to non-ACHD patients while listed for heart transplantation.

63 Overall, 830 noncyanotic ACHD patients (age 36.5 +/- 15.0 years, 49.6% male) fulf

64 ta were collected on consecutive noncyanotic ACHD patients attending our tertiary center between 2001

65 akes into account the distinctive aspects of ACHD patients may help better care for this growing popu

66 should be part of the routine assessment of ACHD patients for risk stratification and treatment when

67 ould be managed by or with the assistance of ACHD cardiologists.

68 g Group reviewed data on the epidemiology of ACHD, long-term outcomes of complex cardiovascular malfo

69 Working groups of ACHD experts reviewed published data and United States,

70 The number of ACHD hospitalizations increased 101.9% from 35,992 +/- 2

71 of this study was to investigate outcomes of ACHD in comparison to non-ACHD patients while listed for

72 There is a growing population of ACHD as the result of advances in pediatric care and dia

73 relevant to patients across the spectrum of ACHD and remarkable homogeneity of patient experience, s

74 ymptoms from patients across the spectrum of ACHD and to examine whether reported symptoms were simil

75 symptoms were similar across the spectrum of ACHD as a foundation for creating a patient-reported out

76 to examine the impact of specialized care on ACHD patient mortality.

77 A lack of qualified ACHD care providers was noted by 76% of PCs.

78 Medical Specialties has recently recognized ACHD as a subspecialty of cardiovascular disease to trea

79 ohort and case-control analyses, specialized ACHD care was independently associated with reduced mort

80 The association between specialized ACHD care and all-cause mortality was assessed in both c

81 Moreover, referral to specialized ACHD care was independently associated with a significan

82 We examined referral rates to specialized ACHD centers and ACHD patient mortality rates between 19

83 ificant increase in referrals to specialized ACHD centers followed the introduction of the clinical g

84 nt increase in referral rates to specialized ACHD centers in 1997 (rate ratio, +7.4%; 95% confidence

85 ortance of specialized follow-up at tertiary ACHD centers has been highlighted.

86 Because many of these ACHD patients are lost to follow-up in adulthood, pregna

87 were less likely to identify this barrier to ACHD care (p = 0.002).

88 The most perceived barrier to ACHD care was emotional attachment of parents and patien

89 at prompt referral and perceived barriers to ACHD care were identified.

90 ondents in the United States provide care to ACHD patients.

91 patient characteristic prompting referral to ACHD care was adult comorbidities (83%).

92 tunity to establish or reestablish care with ACHD specialists and to reestablish continuing long-term

93 ventional risk marker model in patients with ACHD and can reliably exclude the risk of death and hear

94 Clinically stable patients with ACHD who routinely visited the outpatient clinic between

95 e monitoring and management of patients with ACHD.

96 Within ACHD subgroups, peak VO2 gradually declined from aortic